Piper Sandler analyst Christopher Raymond raised the firm’s price target on ALX Oncology to $21 from $11 and keeps an Overweight rating on the shares. The firm sees an increasingly favorable setup for 2024, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALXO:
